| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Avalon GloboCare Corp.$0.28
-0.01 (-1.87%)
F 9Pipeline Score Tools & Services · Clinical
Market Cap
4.44 M
EPS
-9.80
P/E Ratio
-0.04 $
Value Trade
233.42 K
SEC Financials
Q1 2026Dilution Risk
Operating CF
-2.86 M
Total Assets
16.25 M
Total Liabilities
4.52 M
Equity
11.72 M
D/E Ratio
12,345
14.23 %
Week
-3.17 %
1 Month
-32.91 %
3 Month
-76.27 %
6 Month
-99.76 %
5 Year
-99.63 %
All Time
Cash Data
Cash Position
776.00 K
Monthly Burn
953.00 K
Runway
0 mo
Burn Trend
SEC Filing
May 11, 2026
Overview
Volume
103.88 K
52 Week Range
0.21 - 4.74
% held by Insiders
7.19 %
% held by Institutions
11.16 %
Enterprise Value
31.90 M
Total Shares
12.04 M
Short %
2.85 %
Float Shares
7.89 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F9
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 6%
Micro Cap (rank 853 of 906)
Percentile RankAvalon GloboCare Corp. has significant pipeline risk (9/100), with $126M risk-adjusted pipeline value, led by CD19-CAR-T cells in B-cell Malignancy (Phase 1), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD19-CAR-T cells Monoclonal antibody | B-cell Malignancy | Phase 1 | NCT03952923 | 26% | $126M | COMPLETED | 11 | - | - | Mar 31, 2021 | - | Feb 1, 2022 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALBT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALBT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How ALBT ranks across every disease it competes inCompetitive Position is a premium feature
See how ALBT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial